Skip to main content
letter
. 2021 May 13;137(19):2704–2707. doi: 10.1182/blood.2020008119

Figure 2.

Figure 2.

Evidence of differential prognostic association across all subsets of the 23-gene signature. The association of each gene was tested among patients treated with either CHOP/CVP (blue) or bendamustine (red). PFS HRs and 95% CIs from a multivariate Cox proportional-hazards model are plotted. *Demonstrated significant chemotherapy dependence (interaction, P < .05). CI, confidence interval; HR, hazard ratio.